Seattle Genetics, one of the largest biotechnology companies in Washington, is setting the bar with their flagship research into cancer drug development. In an article posted on Seattlebusinessmag.com, Sally James discusses the innovation that seems to drive the successful company. With CEO and co-founder Clay Siegall at the helm, Seattle Genetics is pushing harder than ever to bring their expansive knowledge of pharmaceuticals into global markets by introducing new, revolutionary medications. Of the 11 drugs poised to be released into these new markets, Siegall expresses high hopes for four of them. These four drugs are Adcetris, aimed at Hodgkin’s lymphoma; 33A which will treat acute myeloid leukemia in the future; 22ME a drug working to treat bladder cancer; and LIV1 for breast cancer. Surely, Seattle Genetics is committed to answering the call for better oncological drug technology with their steadfast commitment and strong tenacity.
As CEO and co-founder of Seattle Genetics, Siegall is a strong driving force behind this successful company. In addition to his position of CEO, Siegall also acts as the company’s president and chairman of the board of directors. He also holds a board position at another private biotechnology company, Alder BioPharmaceuticals, strengthening his foothold in the biotechnology field. Prior to the founding of his company in 1998, Siegall gained a lot of useful knowledge in the world of biotechnology from his positions held at Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. It is reasonable to assume that his experiences at both companies helped shape the drive and general trajectory of Seattle Genetics today, building on them to create something truly unique.
In addition to his thriving company, Siegall does not discount the value of personal growth and experience on an individual’s vocational success. He holds both a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland, showing his dedication to his work. He is also an avid contributor to his field, publishing more than 70 works and holding 15 patents. Siegall is always looking for new ways to advance his company for the good of all those individuals that depend on the life-saving products Seattle Genetics offers. As his company continues to grow and contribute to the oncological field, it is apparent that through his work Clay Siegall just may be the driving force needed to help heal the future.